

Supplementary Online Content

Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. *JAMA Cardiol*. Published online April 23, 2020. doi:10.1001/jamacardio.2020.1624

eTable. Characteristics of the hypertension group compared with the non-hypertension group in patients with COVID-19

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Characteristics of the hypertension group compared with the non-hypertension group in patients with COVID-19

	Patients infected COVID-19			
	Total (n=1178)	Hypertension (n=362)	non-Hypertension (n=816)	P
Age, median (IQR), years	55.5 (38.0-67.0)	66.0 (59.0-73.0)	46.0 (34.0-61.0)	< 0.001
Distribution. (%)				
< 40	330 (28.0)	9 (2.5)	321 (39.3)	< 0.001
40-60	382 (32.4)	94 (26.0)	288 (35.3)	
> 60	466 (39.6)	259 (71.5)	207 (25.4)	
Gender, %				
Female	633 (53.7)	173 (47.8)	460 (56.4)	0.006
Male	545 (46.3)	189 (52.2)	356 (43.6)	
Chronic disease, %				
Cerebrovascular disease	95 (8.1)	68 (18.8)	27 (3.3)	< 0.001
Coronary heart disease	103 (8.7)	62 (17.1)	41 (5.0)	< 0.001
Heart failure	21 (1.8)	10 (2.8)	11 (1.3)	0.091
Diabetes	203 (17.2)	127 (35.1)	76 (9.3)	< 0.001
Digestive disorder	167 (14.2)	78 (21.5)	89 (10.9)	< 0.001
Respiratory disease	54 (4.6)	18 (5.0)	36 (4.4)	0.671
Neurological disease	76 (6.5)	38 (10.5)	38 (4.7)	< 0.001
Solid tumor	32 (2.7)	11 (3.0)	21 (2.6)	0.650
Chronic renal disease	44 (3.7)	35 (9.7)	9 (1.1)	< 0.001
Blood biochemical parameters, Median (IQR)				
Leukocytes (3.5-9.5) 10 ⁹ / L	5.2 (4.0-6.7)	5.7 (4.5-7.3)	5.0 (3.8-6.4)	0.009
Neutrophils (1.8-6.3) 10 ⁹ / L	3.3 (2.4-4.7)	3.8 (2.9-5.5)	3.1 (2.2-4.3)	< 0.001
Lymphocytes (1.1-3.2) 10 ⁹ / L	1.2 (0.8-1.6)	1.0 (0.7-1.4)	1.2 (0.9-1.7)	0.002
Platelets (125-350) 10 ⁹ / L	188.0 (148.8-242.0)	186.5 (143.0-246.3)	190.5 (150.0-240.0)	0.554
Hemoglobin (130-175 g/ L)	128.0 (118.0-139.0)	126.0 (113.0-138.0)	129.0 (119.0-140.0)	0.009
Monocytes (0.1-0.6) 10 ⁹ / L	0.4 (0.3-0.5)	0.4 (0.3-0.5)	0.5 (0.3-0.5)	0.185
Activated partial thromboplastin time (20-40) s	27.3 (24.3-31.0)	27.7 (24.6-32.0)	27.2 (24.2-30.6)	0.001
Fibrinogen (2-4) g/ L	2.6 (2.2-3.3)	3.0 (2.5-3.6)	2.5 (2.1-3.1)	< 0.001
Prothrombin time (9-13) s	11.4 (10.8-12.0)	11.5 (10.9-12.2)	11.3 (10.7-11.9)	< 0.001
International Normalized Ratio (0.7-1.3)	1.0 (0.9-1.0)	1.0 (0.9-1.1)	1.0 (0.9-1.0)	< 0.001
D-dimer (0-1) µg/ mL	0.5 (0.2-1.2)	0.7 (0.4-2.2)	0.4 (0.2-0.9)	0.005
Albumin (40-55) g/ L	39.4 (35.4-	37.0 (33.6-40.5)	40.4 (36.7-43.5)	< 0.001

	42.9)			
Globulin (20-40) g/ L	27.4 (24.3-31.5)	27.8 (24.9-32.0)	27.1 (23.8-31.3)	0.202
Albumin-to-globulin ratio (1.2-2.4)	1.4 (1.2-1.7)	1.3 (1.1-1.5)	1.5 (1.2-1.7)	< 0.001
Alanine aminotransferase (9-50) U/ L	19.5 (13.1-33.3)	22.7 (14.1-37.2)	18.5 (12.6-30.9)	0.810
Aspartate aminotransferase (15-40) U/ L	21.0 (16.0-30.5)	24.9 (18.2-36.4)	19.6 (15.2-28.0)	0.001
Total bilirubin (2-20.4) μ mol/ L	9.2 (6.7-13.0)	9.4 (6.8-13.6)	9.1 (6.6-12.8)	0.886
Serum urea (1.7-8.3) mmol/ L	4.1 (3.2-5.5)	5.1 (3.8-6.5)	3.9 (3.1-4.8)	< 0.001
Serum creatinine (57-111) μ mol/ L	64.7 (51.5-79.1)	70.6 (55.3-92.6)	61.5 (50.4-74.7)	< 0.001
Alkaline phosphatase (40-150) U/ L	52.0 (42.0-67.0)	57.0 (44.0-71.0)	51.0 (42.0-66.0)	0.099
Creatine kinase (38-174) U/ L	63.0 (35.0-115.0)	79.5 (45.0-147.7)	57.5 (31.2-98.5)	0.199
Lactate dehydrogenase (80-285) U/ L	165.0 (128.0-216.3)	195.5 (151.8-265.5)	154.0 (120.3-201.0)	< 0.001
Myoglobin (14.3-105.5) ng/ mL	25.5 (14.9-50.3)	35.7 (18.5-83.9)	21.6 (14.4-34.2)	0.605
Troponin (< 0.03) μ g/ L	0.003 (0.000-0.013)	0.008 (0.002-0.030)	0.001 (0.000-0.007)	0.925
Procalcitonin (< 0.04) ng/ mL	0.05 (0.03-0.08)	0.06 (0.04-0.13)	0.04 (0.03-0.06)	0.053
Interleukin 6 (< 7) pg/ mL	4.5 (2.0-15.0)	8.4 (3.8-26.9)	3.5 (1.8-9.7)	0.105
C-reactive protein (0-0.5) mg/ dL	0.8 (0.1-3.6)	2.5 (0.4-5.4)	0.5 (0.1-2.8)	< 0.001
Acute respiratory distress syndrome, %	172 (14.6)	94 (26.0)	78 (9.6)	< 0.001
Severe, %	386 (32.8)	173 (47.8)	213 (26.1)	< 0.001
Non-survivor, %	130 (11.0)	77 (21.3)	53 (6.5)	< 0.001
Hospital stays, median (IQR), days	16.0 (10.0-24.0)	19.0 (12.0-27.0)	15.0 (10.0-22.0)	< 0.001